Neuroprotective Effects of Erinacine A on an Experimental Model of Traumatic Optic Neuropathy

Int J Mol Sci. 2023 Jan 12;24(2):1504. doi: 10.3390/ijms24021504.

Abstract

Erinacine A (EA), a natural neuroprotectant, is isolated from a Chinese herbal medicine, Hericium erinaceus. The aim of this study was to investigate the neuroprotective effects of EA in a rat model of traumatic optic neuropathy. The optic nerves (ONs) of adult male Wistar rats were crushed using a standardized method and divided into three experimental groups: phosphate-buffered saline (PBS control)-treated group, standard EA dose-treated group (2.64 mg/kg in 0.5 mL of PBS), and double EA dose-treated group (5.28 mg/kg in 0.5 mL of PBS). After ON crush, each group was fed orally every day for 14 days before being euthanized. The visual function, retinal ganglion cell (RGC) density, and RGC apoptosis were determined using flash visual-evoked potentials (fVEP) analysis, retrograde Fluoro-Gold labelling, and TdT-dUTP nick end-labelling (TUNEL) assay, respectively. Macrophage infiltration of ON was detected by immunostaining (immunohistochemistry) for ED1. The protein levels of phosphor-receptor-interacting serine/threonine-protein kinase1 (pRIP1), caspase 8 (Cas8), cleaved caspase 3 (cCas3), tumour necrosis factor (TNF)-α, tumour necrosis factor receptor1 (TNFR1), interleukin (IL)-1β, inducible nitric oxide synthase (iNOS), nuclear factor erythroid 2-related factor 2 (Nrf2), haem oxygenase-1 (HO-1), and superoxide dismutase 1 (SOD1) were evaluated by Western blotting. When comparing the standard EA dose-treated group and the double EA dose-treated group with the PBS-treated group, fVEP analysis showed that the amplitudes of P1−N2 in the standard EA dose group and the double EA dose-treated group were 1.8 and 2.4-fold, respectively, higher than that in the PBS-treated group (p < 0.05). The density of RGC in the standard EA dose-treated group and the double EA dose-treated group were 2.3 and 3.7-fold, respectively, higher than that in the PBS-treated group (p < 0.05). The TUNEL assay showed that the standard EA dose-treated group and the double EA dose-treated group had significantly reduced numbers of apoptotic RGC by 10.0 and 15.6-fold, respectively, compared with the PBS-treated group (p < 0.05). The numbers of macrophages on ON were reduced by 1.8 and 2.2-fold in the standard EA dose-treated group and the double EA dose-treated group, respectively (p < 0.01). On the retinal samples, the levels of pRIP, Cas8, cCas3, TNF-α, TNFR1, IL-1β, and iNOS were decreased, whereas those of Nrf2, HO-1, and SOD1 were increased in both EA-treated groups compared to those in the PBS-treated group (p < 0.05). EA treatment has neuroprotective effects on an experimental model of traumatic optic neuropathy by suppressing apoptosis, neuroinflammation, and oxidative stress to protect the RGCs from death as well as preserving the visual function.

Keywords: Erinacine A; Hericium erinaceus; Nrf2; anti-inflammation; antiapoptosis; antioxidant; oxidative stress; pRIP; traumatic optic neuropathy.

MeSH terms

  • Animals
  • Apoptosis
  • Disease Models, Animal
  • Male
  • Models, Theoretical
  • NF-E2-Related Factor 2
  • Neuroprotective Agents* / pharmacology
  • Neuroprotective Agents* / therapeutic use
  • Optic Nerve Injuries* / metabolism
  • Rats
  • Rats, Wistar
  • Receptors, Tumor Necrosis Factor, Type I
  • Superoxide Dismutase-1
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • Neuroprotective Agents
  • erinacine A
  • NF-E2-Related Factor 2
  • Receptors, Tumor Necrosis Factor, Type I
  • Superoxide Dismutase-1
  • Tumor Necrosis Factor-alpha

Grants and funding

This research was funded by the research project grant of the Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taiwan, under Grant no. TCMF-EP-108-01.